-
Product Insights
NewNet Present Value Model: Ascendis Pharma AS’s TC-TLR7/8
Empower your strategies with our Net Present Value Model: Ascendis Pharma AS's TC-TLR7/8 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TC-110 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TC-110 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TC-110 in Acute Lymphocytic Leukemia (ALL,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TC-110 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TC-110 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TC-110 in Follicular Lymphoma Drug Details: TC-110 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TC-110 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TC-110 in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TC-110 in Mantle Cell Lymphoma Drug Details: TC-110 is under development...
-
Thematic Analysis
NewIT Services Sector Scorecard, Q1 2024 Update – Thematic Intelligence
Companies scoring well in the cloud, data analytics, and future of work themes lead the thematic screen of GlobalData’s IT services sector scorecard. This is dominated by the global IT services giants Accenture, IBM, and Infosys, closely followed by Capgemini and Tata Consultancy Services (TCS). Indian heritage vendors occupy half of the top 10 vendor positions, suggesting they are successfully adapting their strategies to the long-term concern of a declining cost advantage versus their US and European peers.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pralsetinib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pralsetinib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pralsetinib in Solid Tumor Drug Details: Pralsetinib (Gavreto) is an anticancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TC-110 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TC-110 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TC-110 in Acute Lymphocytic Leukemia (ALL, Acute...
-
Thematic Analysis
NewOil and Gas M&A Deals, Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Oil & Gas Sector
-
Thematic Analysis
NewAutomotive M&A Deals, Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Automotive Sector
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab in Lung Cancer Drug Details: Atezolizumab (Tecentriq) is an antineoplastic...